Eli Lilly disclosed in a filing with the US Securities and Exchange Commission that it has been subpoenaed by the New York Attorney General's Office over the pricing and sales of its insulin products, reported CNBC.
The drugmaker noted that attorney general offices in Mississippi, Washington DC, California, Florida, Hawaii and Nevada are also seeking information regarding its pricing.
Sanofi recently disclosed that it, along with Eli Lilly and Novo Nordisk had received a subpoena from New York's Attorney General.
However, Eli Lilly has argued that after factoring in rebates and discounts, its products' net price has actually decreased over the years.
Earlier this year in a preemptive move, the drugmaker launched a half-price version of Humalog, with the rebranded product, called Insulin Lispro, priced at $137.35 per vial.
To read more NewsPoints articles, click here.